| Manishkumar Patel, MD | |
|
781 Lakeshire Trl, Adrian, MI 49221-1561 | |
| (517) 265-0600 | |
| Not Available |
| Full Name | Manishkumar Patel |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 781 Lakeshire Trl, Adrian, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245717339 | NPI | - | NPPES |
| Entity Name | Promedica Central Corporation Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588624696 PECOS PAC ID: 7012902265 Enrollment ID: O20040416001163 |
News Archive
Microfluidic Systems, a privately-held company, announced today that they received an award from Inc. Magazine. The Fourth Annual Exclusive List of America's Fastest-Growing Private Companies—the Inc. 5000 ranked Microfluidic Systems number 3035 with a growth rate of 68%. The list represents the most comprehensive look at the most important segment of the economy—America's independent-minded entrepreneurs.
For respiratory infections in children under 12, physicians are increasingly more likely to recommend antihistamines and less likely to recommend cough and cold medicines, a Rutgers study found.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company's newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL's U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.
Merck, known as MSD outside the United States and Canada, today announced that its Board of Directors has approved additional purchases of up to $5 billion of Merck's common stock for its treasury. The treasury stock purchase has no time limit and will be made over time on the open market, in block transactions or in privately negotiated transactions.
A treatment regimen including high-dose rifampicin administered intravenously in addition to standard or high-dose moxifloxacin has an acceptable safety profile and could improve survival for patients with tuberculous meningitis, indicate phase II trial results.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Manishkumar Patel, MD 333 N Summit St Fl 7, Toledo, OH 43604-1531 Ph: () - | Manishkumar Patel, MD 781 Lakeshire Trl, Adrian, MI 49221-1561 Ph: (517) 265-0600 |
News Archive
Microfluidic Systems, a privately-held company, announced today that they received an award from Inc. Magazine. The Fourth Annual Exclusive List of America's Fastest-Growing Private Companies—the Inc. 5000 ranked Microfluidic Systems number 3035 with a growth rate of 68%. The list represents the most comprehensive look at the most important segment of the economy—America's independent-minded entrepreneurs.
For respiratory infections in children under 12, physicians are increasingly more likely to recommend antihistamines and less likely to recommend cough and cold medicines, a Rutgers study found.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company's newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL's U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.
Merck, known as MSD outside the United States and Canada, today announced that its Board of Directors has approved additional purchases of up to $5 billion of Merck's common stock for its treasury. The treasury stock purchase has no time limit and will be made over time on the open market, in block transactions or in privately negotiated transactions.
A treatment regimen including high-dose rifampicin administered intravenously in addition to standard or high-dose moxifloxacin has an acceptable safety profile and could improve survival for patients with tuberculous meningitis, indicate phase II trial results.
› Verified 5 days ago
Dr. Wayne A Smith, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 781 Lakeshire Trail, Adrian, MI 49221 Phone: 517-265-0600 Fax: 517-263-0024 | |
Hemlata Bhaskar, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 781 Lakeshire Trail, Adrian, MI 49221 Phone: 517-263-2187 Fax: 517-263-0024 | |
Dr. Paul E Gietzen Jr., M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 781 Lakeshire Trl, Adrian, MI 49221 Phone: 517-263-2187 Fax: 517-263-0024 | |
Jeffrey B Mcclure, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 818 Riverside Ave, 5th Floor Cardiology, Adrian, MI 49221 Phone: 517-265-0326 Fax: 517-265-0313 | |
Dr. Michael T Mcauliffe, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 818 Riverside Ave, Adrian, MI 49221 Phone: 517-265-0900 | |
Dr. Charan Kanwal Cheema, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 781 Lakeshire Trl, Adrian, MI 49221 Phone: 517-265-0600 | |
Dr. Inad Haddad, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1548 W Maumee St, Adrian, MI 49221 Phone: 517-263-7577 Fax: 517-263-6643 |